Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma

  • Noopur S. Raje, Philippe Moreau, Evangelos Terpos, Lotfi Benboubker, Norbert Grząśko, Sarah A. Holstein, Albert Oriol, Shang-Yi Huang, Meral Beksac, Kazimierz Kuliczkowski, Datchen F. Tai, James E. Wooldridge, Ilaria Conti, Christopher J. Kaiser, Tuan S. Nguyen, Damien M. Cronier, Antonio Palumbo
  • British Journal of Haematology, December 2016, Wiley
  • DOI: 10.1111/bjh.14483

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

The following have contributed to this page: Dr Albert Oriol